Four recent press articles

We’re excited about our recent press coverage, which reflects our increasing momentum and progress in developing our technology as well as advancing our partnering business. In fact, there are four recent articles that we wanted to bring to your attention:

The first, from the San Francisco Business Times, paints a high-level picture of the parallels between our approach to ranking molecules and strategies such as Google’s PageRank. We are particularly excited that the article highlighted what we believe to be our most compelling competitive advantage — our ability to deliver white powder in vials that performs as predicted in the lab.

http://www.portfolio.com/industry-news/health-care/2010/08/25/numerate-uses-technology-to-choose-which-drugs-to-advance

This article from FierceBiotech IT, expands on the Business Times piece and discusses the patent we were granted covering our novel application of machine-learning technology to challenges in drug discovery.

http://www.fiercebiotechit.com/story/report-google-code-tackles-drug-development/2010-08-20

We were pleased that BioCentury chose to feature Numerate in an “Emerging Company Profile,” which provides an in-depth look at our technology and describes the progress we’ve made since founding the company in 2007.

http://www.biocentury.com/biotech-pharma-news/emergingcompany/2010-08-23/numerate-believes-its-in-silico-drug-design-produces-less-risky-small-molecules-a13

Finally, BioWorld ran an item announcing the successful completion of our collaboration with Intellikine, noting that we were able to deliver backups for Intellikine’s already impressive lead series for PI3K–alpha inhibitors.

We will keep you apprised of similar articles in the future as we continue to grow our business, build our technology, and meet significant milestones, both for us and for our partners.